Drugs Made In Am (DMIIR) Stock Price, News & Analysis
Company Description
Drugs Made In Am (NASDAQ: DMIIR) is classified in the Blank Checks sector.
For FY2025, Drugs Made In Am reported net income of $4.2M.
This page collects what Stock Titan holds for DMIIR, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Drugs Made In Am (DMIIR) stock last closed at $0.0800.
Latest News
SEC Filings
Drugs Made In Am has filed 5 recent SEC filings, including 3 Form 8-K, 1 Form 10-Q, 1 Form 10-K. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DMIIR SEC filings →
Financial Highlights
operating income reached -$488K, and net income was $4.2M. The company generated -$1.0M in operating cash flow. With a current ratio of 0.09, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Drugs Made In Am (DMIIR) currently stands at 18.8 thousand shares, down 7.8% from the previous reporting period. Since December 2025, short interest has increased by 4590.3%.
Days to Cover History
Days to cover for Drugs Made In Am (DMIIR) currently stands at 1.0 days, down 91.1% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 11.7 days.
DMIIR Company Profile & Sector Positioning
Drugs Made In Am (DMIIR) operates in the Blank Checks sector and is listed on the NASDAQ.